Cargando…

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

BACKGROUND: Extending the duration of adjuvant endocrine therapy reduces the risk of recurrence in a subset of women with early-stage hormone receptor-positive (HR+) breast cancer. Validated predictive biomarkers of endocrine response could significantly improve patient selection for extended therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartlett, J M S, Sgroi, D C, Treuner, K, Zhang, Y, Ahmed, I, Piper, T, Salunga, R, Brachtel, E F, Pirrie, S J, Schnabel, C A, Rea, D W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927322/ https://www.ncbi.nlm.nih.gov/pubmed/31504126 http://dx.doi.org/10.1093/annonc/mdz289

Ejemplares similares

Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
por: Bartlett, John M.S., et al.
Publicado: (2022)

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
por: Sgroi, Dennis C., et al.
Publicado: (2022)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

The role of Nanog expression in tamoxifen-resistant breast cancer cells
por: Arif, Khalid, et al.
Publicado: (2015)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
por: Lissoni, P., et al.
Publicado: (1995)

AttOmics: attention-based architecture for diagnosis and prognosis from omics data
por: Beaude, Aurélien, et al.
Publicado: (2023)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line
por: Won, Hye Sung, et al.
Publicado: (2016)

Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients
por: Lima, Mariana Tavares Miranda, et al.
Publicado: (2017)

Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells
por: Candelaria, Nicholes R., et al.
Publicado: (2015)

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer
por: Buijs, S.M., et al.
Publicado: (2023)

ROS Generative Black Phosphorus-Tamoxifen Nanosheets for Targeted Endocrine-Sonodynamic Synergistic Breast Cancer Therapy
por: Wang, Jing, et al.
Publicado: (2023)

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases
por: MADEDDU, CLELIA, et al.
Publicado: (2014)

The mechanism of tamoxifen in breast cancer prevention
por: Yu, F, et al.
Publicado: (2001)

Breast cancer chemoprevention: beyond tamoxifen
por: Fabian, Carol J
Publicado: (2001)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors
por: Uslu, Yasemin, et al.
Publicado: (2023)

Proceedings: Hormones in breast cancer patients on tamoxifen.
por: Golder, M. P., et al.
Publicado: (1975)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Endocrine Relationships in Breast Cancer
por: Barnes, D. M.
Publicado: (1982)

Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant)
por: Chan, Carmen Wing Han, et al.
Publicado: (2020)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
por: Løkkegaard, Sanne, et al.
Publicado: (2021)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
por: Pinzón-García, Ana D., et al.
Publicado: (2021)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Rosso, Roberta, et al.
Publicado: (2023)

Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
por: Nunes, Raquel, et al.
Publicado: (2021)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.
Publicado: (1988)

Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
por: Al-Mubarak, Mustafa, et al.
Publicado: (2014)

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
por: Pistilli, Barbara, et al.
Publicado: (2020)

Tamoxifen for women at high risk of breast cancer
por: Nazarali, Safia A, et al.
Publicado: (2014)

Combination Treatment of Tamoxifen with Risperidone in Breast Cancer
por: Yeh, Wei-Lan, et al.
Publicado: (2014)

Molecular prediction of tamoxifen resistance in breast cancer
por: Kok, M, et al.
Publicado: (2005)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy
por: Huang, Xuchen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9rsrfgkihg3f7agth0p2td80ei